Cargando…
Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic
Autores principales: | Jena, Anuraag, Kumar-M, Praveen, Singh, Anupam Kumar, Sharma, Vishal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572109/ https://www.ncbi.nlm.nih.gov/pubmed/33132062 http://dx.doi.org/10.1016/j.dld.2020.10.021 |
Ejemplares similares
-
Systematic review on failure to adhere to IBD therapies during the COVID-19 pandemic: Correct information is crucial
por: Jena, Anuraag, et al.
Publicado: (2020) -
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta‐analysis
por: Singh, Anupam Kumar, et al.
Publicado: (2021) -
Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Singh, Anupam K., et al.
Publicado: (2022) -
Fecal calprotectin in inflammatory bowel disease
por: Walsham, Natalie E, et al.
Publicado: (2016) -
The Usefulness of Fecal Calprotectin in the era of the COVID-19 Pandemic
por: Mago, Sheena, et al.
Publicado: (2021)